Staying Power

Publisher Website
Google Scholar
Abstract
The largest study to evaluate the oral therapy imatinib (Glivec/STI571) in patients with chronic myeloid leukaemia (CML) reported a survival rate of nearly 90% after 5 years of treatment.Five-year follow-up data from the International Randomized Interferon versus STI571 (IRIS) trial were presented at the American Society of Clinical Oncology annual meeting.

This publication has 0 references indexed in Scilit: